These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 576423)

  • 1. Plasma clofibric acid (CPIB) levels induced by three marketed compounds releasing clofibric acid, in volunteers.
    Harvengt C; Desager JP
    Int J Clin Pharmacol Biopharm; 1977 Jan; 15(1):1-4. PubMed ID: 576423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic study and bioavailability of three marketed compounds releasing p-chlorophenoxyisobutyric acid (CPIB) in volunteers.
    Harvengt C; Desager JP
    Int J Clin Pharmacol Biopharm; 1976 Sep; 14(2):113-8. PubMed ID: 1002348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clofibrate and clofibric acid: comparison of the metabolic disposition in rats and dogs.
    Cayen MN; Ferdinandi ES; Greselin E; Robinson WT; Dvornik D
    J Pharmacol Exp Ther; 1977 Jan; 200(1):33-43. PubMed ID: 833760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability studies of etofibrate in rhesus monkeys.
    Waller AR; Chasseaud LF; Taylor T; Schatton W
    Arzneimittelforschung; 1985; 35(2):489-92. PubMed ID: 4039571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A quantitative gaschromatographic method for the determination of p-chlorophenoxyisobutyric acid (clofibrinic acid) in human plasma (author's transl)].
    Häselbarth V
    Arzneimittelforschung; 1976; 26(11):2076-80. PubMed ID: 1037251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concentration of clofibric acid in blood after the administration of delayed-release form of etofibrate.
    Vazquez Lopez F; Armijo Castro F; Pire Solis I; Gutierrez Fuentes JA
    Int J Clin Pharmacol Ther Toxicol; 1987 Jan; 25(1):31-5. PubMed ID: 3557726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative bioavailability of etofibrate. A comparison of an acute and a new sustained release formulation.
    Johnson KI; Hoppe HJ; Schatton W
    Arzneimittelforschung; 1984; 34(12):1785-7. PubMed ID: 6543315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Species differences in the metabolic conjugation of clofibric acid and clofibrate in laboratory animals and man.
    Emudianughe TS; Caldwell J; Sinclair KA; Smith RL
    Drug Metab Dispos; 1983; 11(2):97-102. PubMed ID: 6133730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma concentrations and bioavailability of clofibric acid from its calcium salt in humans.
    Taylor T; Chasseaud LF
    J Pharm Sci; 1977 Nov; 66(11):1638-9. PubMed ID: 915750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic].
    Lücker PW; Wetzelsberger K; Erking W; Donike M
    Arzneimittelforschung; 1980; 30(11b):2045-53. PubMed ID: 7194058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dependent pharmacokinetics of clofibric acid in the non-human primate.
    Walmsley LM
    Arch Toxicol Suppl; 1984; 7():272-7. PubMed ID: 6595991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced clofibric acid clearance in renal dysfunction is due to a futile cycle.
    Meffin PJ; Zilm DM; Veenendaal JR
    J Pharmacol Exp Ther; 1983 Dec; 227(3):732-8. PubMed ID: 6655566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetic study in man of hypolipemic agents derived from clofibric acid after single and repeated administration].
    Cailleux A; Allain P; Tadei A
    Therapie; 1976; 31(5):637-45. PubMed ID: 1013956
    [No Abstract]   [Full Text] [Related]  

  • 14. Suprofen sustained release kinetics in healthy male volunteers. 1st communication: a single dose open crossover bioavailability study of suprofen sustained release tablets versus capsules.
    Michos N; Zulliger HW; Barkworth MF; Johnson KJ; Rehm KD; Töberich H; Klein G
    Arzneimittelforschung; 1986 Jun; 36(6):941-8. PubMed ID: 3741528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Branched chain amino acid oxidation in cultured rat skeletal muscle cells. Selective inhibition by clofibric acid.
    Pardridge WM; Casanello-Ertl D; Duducgian-Vartavarian L
    J Clin Invest; 1980 Jul; 66(1):88-93. PubMed ID: 7400311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioavailability of plafibride in healthy volunteers.
    Santaniello E; Conti F; Vilageliu J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1850-2. PubMed ID: 7198464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers.
    Abshagen U; Spörl-Radun S; Marinow J
    Eur J Clin Pharmacol; 1980 Apr; 17(4):305-8. PubMed ID: 6995131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A renal mechanism for the clofibric acid-probenecid interaction.
    Meffin PJ; Zilm DM; Veenendaal JR
    J Pharmacol Exp Ther; 1983 Dec; 227(3):739-42. PubMed ID: 6655567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of adimolol after single and multiple dose administration in healthy volunteers.
    Wiedemann I; Peil H; Justus H; Adamus S; Brantl V; Lohmann H
    Arzneimittelforschung; 1985; 35(6):964-9. PubMed ID: 2862877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.